Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancerJessica Armand(Columbia University Irving Medical Center)eLifeJanuary 27, 202510.7554/elife.104545Cited by 3SaveCiteExport RISWatch citationsRelated PapersTherapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer|eLife|2025|0